Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry

被引:7
作者
Maldini, Colby R. [1 ]
Love, Andrea C. [2 ]
Tosh, Kevin W. [1 ]
Chan, Leo Li-Ying [2 ]
Gayout, Kevin [1 ]
Smith, Tim [2 ]
Riley, James L. [1 ]
机构
[1] Univ Penn, Ctr Cellular Immunotherapies, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA
[2] Nexcelom Biosci LLC, Dept Technol R&D, Lawrence, MA 01843 USA
关键词
Image cytometry; Chimeric antigen receptor (CAR) T cells; Cell-mediated cytotoxicity; CAR T cell manufacturing; Bioluminescence (BLI)-based cytotoxicity assay; IN-VITRO; RECEPTOR; PATHWAYS; ASSAY; CD28;
D O I
10.1016/j.jim.2020.112830
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Since the FDA approval of two Chimeric Antigen Receptor (CAR) T cell therapies against CD19(+) malignancies, there has been significant interest in adapting CAR technology to other diseases. As such, the ability to simultaneously monitor manufacturing criteria and functional characteristics of multiple CAR T cell products by a single instrument would likely accelerate the development of candidate therapies. Here, we demonstrate that image-based cytometry yields high-throughput measurements of CAR T cell proliferation and size, and captures the kinetics of in vitro antigen-specific CAR T cell-mediated killing. The data acquired and analyzed by the image cytometer are congruent with results derived from conventional technologies when tested contemporaneously. Moreover, the use of bright-field and fluorescence microscopy by the image cytometer provides kinetic measurements and rapid data acquisition, which are direct advantages over industry standard instruments. Together, image cytometry enables fast, reproducible measurements of CAR T cell manufacturing criteria and effector function, which can greatly facilitate the evaluation of novel CARs with therapeutic potential.
引用
收藏
页数:9
相关论文
empty
未找到相关数据